Form 4: Vertex Pharmaceuticals EVP David Altshuler Reports Stock Transactions
SEC Form 4 Filing
David Altshuler, EVP of Global Research and CSO at Vertex Pharmaceuticals, reports the disposition of company stock on February 23 and 26, 2024, according to a Form 4 filing.
Summary
- David Altshuler, EVP, Global Research and CSO of Vertex Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership of company stock.
- On February 23, 2024, 3,970 shares of common stock were disposed of at a price of $431.79.
- On February 26, 2024, 4,239 shares of common stock were sold at a price of $425.7.
- Following these transactions, Altshuler directly owns 25,813 shares of Vertex Pharmaceuticals stock.
- The sale on February 26, 2024, was executed under a pre-arranged trading plan (Rule 10b5-1) established on May 10, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions made under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. Rule 10b5-1 plans allow insiders to sell shares over a predetermined period, mitigating concerns about insider trading.
Stakeholder Impact
- The stock sales by a high-ranking executive could be perceived negatively by some shareholders, potentially leading to slight selling pressure.
- However, the existence of a pre-arranged trading plan mitigates concerns about insider information driving the sales.
Key Dates
| Date | Description |
|---|---|
| 05/10/2023 | Date of entry into Rule 10b5-1 trading plan |
| 02/23/2024 | Date of transaction: Disposition of 3,970 shares |
| 02/26/2024 | Date of transaction: Sale of 4,239 shares |
| 02/27/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.